Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice

Fabio Guarracino, MD, PhD,* Matthias Heringlake, MD, PhD,† Bernard Cholley, MD, PhD,‡ Dominique Bettex, MD, PhD,¶ Stefaan Bouchez, MD, PhD,|| Vladimir V. Lomivorotov, MD, PhD,** Angela Rajek, MD,†† Matti Kivikko, MD, PhD,‡‡§§ and Piero Pollesello, PhD‡‡§§

Abstract: Levosimendan is a calcium sensitizer and adenosine triphosphate–dependent potassium channel opener, which exerts sustained hemodynamic, symptomatic, and organ-protective effects. It is registered for the treatment of acute heart failure, and when inotropic support is considered appropriate. In the past 15 years, levosimendan has been widely used in clinical practice and has also been tested in clinical trials to stabilize at-risk patients undergoing cardiac surgery. Recently, 3 randomized, placebo-controlled, multicenter studies (LICORN, CHEETAH, and LEVO-CTS) have been published reporting on the perioperative use of levosimendan in patients with compromised cardiac ventricular function. Taken together, many smaller trials conducted in the past suggested beneficial outcomes with levosimendan in perioperative settings. By contrast, the latest 3 studies were neutral or inconclusive. To understand the reasons for such dissimilarity, a group of experts from Austria, Belgium, Finland, France, Germany, Italy, Switzerland, and Russia, including investigators from the 3 most recent studies, met to discuss the study results in the light of both the previous literature and current clinical practice. Despite the fact that the null hypothesis could not be ruled out in the recent multicenter trials, we conclude that levosimendan can still be viewed as a safe and effective modulator in cardiac surgery.

Key Words: cardiac surgery, clinical trials, levosimendan, systematic review, opinion paper

(J Cardiovasc Pharmacol™ 2018;71:1–9)

INTRODUCTION

Perioperative mortality is reported to be as low as 1%–4% in the general elective surgery population.¹ However, in patients with postoperative low cardiac output syndrome (LCOS), mortality is considerably higher.² In addition to higher mortality, LCOS predisposes patients to postoperative myocardial injury, renal failure, and prolonged intensive care unit (ICU) and hospital stay.³ Several baseline factors, such as preoperatively reduced left (and/or right) ventricular function or recent myocardial infarction, predispose patients to LCOS.⁴ The type of surgery also affects the postoperative risk profile; coronary artery bypass grafting (CABG) alone has a more benign outcome than, for example, the combination of CABG and a valve replacement.⁵

LCOS is managed with inotropic agents and/or mechanical cardiac assist devices such as an intraaortic balloon pump (IABP). Even so, short-term mortality is greatly elevated versus non-LCOS comparators.⁶ Moreover, the inotropic agents traditionally used in this setting have conspicuous adverse effects or incompletely defined safety profiles.⁷ Levosimendan is a calcium sensitizer and adenosine triphosphate (ATP)-dependent potassium channel opener with positive inotropic, vasodilatory, and cardioprotective properties.⁸ The drug binds to cardiac troponin C in a calcium-dependent manner,⁹,¹⁰ which mediates the positive inotropic effect by increasing the calcium sensitivity of myocytes. The vasodilatory effect is due to the opening of ATP-sensitive potassium channels in vascular smooth muscle, resulting in its relaxation. By opening mitochondrial ATP-sensitive
potassium channels in cardiomyocytes, the drug also exerts a cardioprotective effect. In addition, inhibition of phosphodiesterase III by levosimendan has been also proposed to have a role in its pharmacodynamics effects.\textsuperscript{11}

Levosimendan has been in clinical use for 15 years. In addition to its original indication for acutely decompensated heart failure, it has also been used to stabilize patients undergoing cardiac surgery. Abundant literature from exploratory studies supports the rationale for its use in this indication,\textsuperscript{12} and this is also supported by its benign effect on kidney function.\textsuperscript{13}

Recently, 3 randomized, placebo-controlled, multicenter studies were published on the perioperative use of levosimendan: LICORN,\textsuperscript{14} CHEETAH,\textsuperscript{15} and LEVO-CTS.\textsuperscript{16} In contrast to the many preceding smaller trials which, either individually or as a whole, produced a promising image of levosimendan in perioperative settings, these latest 3 studies were either neutral or inconclusive.

A group of experts from 8 European countries (Austria, Belgium, Finland, France, Germany, Italy, Switzerland, and Russia), including investigators from the 3 most recent studies on the preoperative, perioperative, and postoperative use of levosimendan, met on April 20, 2017 in occasion of the EACTA annual congress in Berlin, Germany, to discuss the recent study results in the light of both the previous literature and current clinical practice. The present article was created from the proceedings of that discussion.

PREVIOUS RELEVANT STUDIES ON THE USE OF LEVOSIMENDAN IN CARDIAC SURGERY

Levosimendan has been studied in >40 clinical trials in cardiac surgery. Earlier studies suggested that it could prevent the development of LCOS and be effective in treating postoperative LCOS (Box 1). The level of proof, however, remained low, despite a meta-analysis that suggested a survival benefit in patients with low preoperative ejection fraction (EF).\textsuperscript{17} Indications of renal-protective effects in this setting have also been reported in retrospective analyses.\textsuperscript{18,19}

The individual and aggregate findings of the 14 studies in cardiac surgery patients with low left ventricular EF (LVEF) examined by Harrison et al\textsuperscript{17} in their meta-analysis are reported in Figure 1, and the results of the contributing studies are summarized briefly in Table 1.\textsuperscript{20–33}

In total, Harrison et al took into consideration data from 1155 patients (84 deaths) and the overall effect of levosimendan versus comparator was significant (P = 0.008). Visual inspection of the funnel plot for the primary outcome of mortality was not suggestive of significant publication bias. However, removal of either of the 2 studies by Levin et al\textsuperscript{25,26} made the overall estimated effect of levosimendan on mortality insignificant.

For the sake of completeness, we report that, in addition to the 14 articles considered by Harrison et al, other relevant studies conducted on levosimendan in surgical patients are those by Severi et al\textsuperscript{34} and Lomivorotov et al\textsuperscript{35} on levosimendan versus IABP; the trials by Baysal et al\textsuperscript{36} and Erb et al\textsuperscript{37} on renal outcome and organ dysfunction, respectively; and the randomized pilot study on prophylactic use of levosimendan by Anastasiadis et al.\textsuperscript{38}

THE 3 MOST RECENT STUDIES

Three larger clinical studies have recently been conducted with levosimendan in patients undergoing cardiac surgery. All 3 were randomized, placebo-controlled, multicenter studies. The LICORN and CHEETAH studies were investigator-initiated studies, whereas LEVO-CTS was a phase 3 regulatory study (Box 2). Broad outlines of the study designs and their primary findings are given below.

**BOX 2.**

The 3 Most Recent Studies on Levosimendan in Cardiac Surgery

- **LICORN:** Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass trial (NCT02184819) assessing the efficacy of a preoperative infusion of levosimendan in reducing postoperative LCOS in patients with poor LVEF undergoing CABG;
- **CHEETAH:** Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients trial (NCT00994825) assessing the effect of levosimendan on cardiac surgery patients who developed postoperative LCOS;
- **LEVO-CTS:** Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass, phase III clinical trial (NCT02025621) assessing the effect of levosimendan on patients with low preoperative LVEF (EF < 35%) undergoing scheduled or urgent cardiac surgery.

**LICORN**

The LICORN trial (Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With
A cohort of 336 patients with LVEF ≤ 0.15. Of 3m This is at variance with the summary of product character-

istics guidance, according to which 1 vial of Simdax (12.5 mg levosimendan concentrate for intravenous use) should be diluted in at least 250 mL of 5% glucose solution (1:50). There is a risk of precipitation if smaller diluent volumes are used and this exposes the patient to unpredictable dosing (ie, receipt of less than the intended dose).

Cardiopulmonary Bypass; NCT02184819) assessed the efficacy of a preoperative infusion of levosimendan in reducing postoperative LCOS in patients with poor LVEF undergoing CABG. A cohort of 336 patients with LVEF ≤40% undergoing CABG was recruited from 13 French hospitals. The study drug was started after induction of anesthesia and infused over a period of 24 hours at a rate of 0.1 μg·kg⁻¹·min⁻¹. Postoperative LCOS was evaluated using a composite criterion comprising (1) need for inotropic agents beyond 48 hours after initiation of the study drug; (2) need for postoperative mechanical assist devices or failure to wean from these devices when initiated preoperatively; and (3) need for renal replacement therapy.

The primary end point was observed in 87/167 patients (52%) in the levosimendan group, compared with 101/168 (61%) in the placebo group [absolute risk reduction = 7%, 95% confidence interval (CI), −17% to +3%, P = 0.15]. Of the secondary end points, the duration of catecholamine treatment was shorter in the levosimendan group: 3.2 ± 3.6 versus 4.1 ± 4.3 days (P = 0.021). However, no adjustment was made for multiple comparisons, and this result should be considered exploratory. There were no statistically significant intergroup differences in mortality or length of ICU stay.

The lack of statistical significance in the composite primary end point was likely contributed to by the fact that the observed event rate in the placebo arm was lower than that anticipated (61% vs. 65%); it was anticipated also that the prevalence rate would be reduced to 50% in the levosimendan group, but the prevalence actually observed was 52% in the intention-to-treat population (vs. 51% in the per-protocol population). LICORN was powered according to an expectation of an absolute risk reduction of 15%. The point estimate actually recorded was 7% and favored levosimendan, but the 95% CI included a reduction of 17% (range −17% to +3%). The observed effect was less than that anticipated by the study hypothesis; however, the study was underpowered to definitely exclude a meaningful beneficial effect of levosimendan on the primary composite outcome.

CHEEAH

In the CHEEAH (Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients; NCT00994825) trial, levosimendan or placebo was administered to cardiac surgery patients, who, according to predefined criteria, developed postoperative LCOS. In total, 1000 patients were scheduled to be included and the primary end point was 30-day mortality. The study was performed in 14 centers in Italy, Russia, and Brazil but was stopped for futility after 506 patients had been enrolled. A total of 248 patients received levosimendan and 258 received placebo. The mean infusion rate and duration of levosimendan were 0.07 μg·kg⁻¹·min⁻¹ for 33 hours, and the median EF was 50% in both groups, with 11% of patients having an EF of <25%. There was no significant difference in 30-day mortality between the levosimendan and placebo groups: 32 patients (12.9%) versus 33 (12.8%); absolute risk difference 0.1 percentage points; 95% CI, −5.7 to +5.9 percentage points; P = 0.97. There were no significant between-group differences in other end points and no difference in the rates of adverse events (hypotension or arrhythmias).

It should be noted that, in the report of the CHEEAH study, preparation of the study drug was described as follows: “levosimendan was diluted as 12.5 mg in 100 mL of 5% glucose.” This is at variance with the summary of product characteristics guidance, according to which 1 vial of Simdax (12.5 mg levosimendan concentrate for intravenous use) should be diluted in at least 250 mL of 5% glucose solution (1:50). There is a risk of precipitation if smaller diluent volumes are used and this exposes the patient to unpredictable dosing (ie, receipt of less than the intended dose).

LEVO-CTS

This study (Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass; NCT02025621) was a phase III clinical trial sponsored by TENAX Therapeutics Inc, run by Duke University (Durham, NC) and configured to...
### TABLE 1. Studies on the Use of Levosimendan in Perioperative Settings Included in the Meta-analysis by Harrison et al17

| First Author, Year of Publication (ref) | Settings | Trial Design | LS Dose | Start of Treatment | Comparator | Patients in LS Arm vs. Comparator | Primary End Points/Evaluations | Secondary End Points/Evaluations |
|----------------------------------------|----------|--------------|----------|--------------------|------------|----------------------------------|-------------------------------|---------------------------------|
| Al-Shawaf et al, 200620                | Postoperative LCOS (within 12 h) in patients with type 2 DM and preoperative LVEF <35%, to whom CABG was performed | Randomized open label | 12 μg/kg bolus + 0.1–0.2 μg·kg⁻¹·min⁻¹ for 24 h | Within 12 h after surgery | Milrinone 50 μg/kg bolus + 0.3–0.5 μg·kg⁻¹·min⁻¹ for 24 h | 14 vs. 16 | Superior hemodynamic effects (cardiac index and mixed venous saturation) with LS | No difference in insulin requirements Time in ventilator and ICU shorter with LS |
| Alvarez et al, 200521                  | Postoperative cardiac index <2.5 L·min⁻¹·m⁻² in patients to whom CABG was performed | Randomized open label | 12 μg/kg bolus + 0.2 μg·kg⁻¹·min⁻¹ for 24 h | After surgery | Dobutamine 7.5 μg·kg⁻¹·min⁻¹ for 24 h | 15 vs. 15 | Cardiac index and heart rate increased, and mean arterial pressure, systemic, and pulmonary vascular index decreased significantly in LS group | The hemodynamic effects lasted beyond the study drug infusion period only in LS group |
| Alvarez et al, 200622                  | Postoperative LCOS (within 4 h) in patients to whom CABG or valvular surgery was performed | Randomized open label | 12 μg/kg bolus + 0.2 μg·kg⁻¹·min⁻¹ for 24 h | Within 4 h after surgery | Dobutamine 7.5 μg·kg⁻¹·min⁻¹ for 24 h | 25 vs. 25 | More pronounced heart rate and cardiac index increase, and more pronounced decrease in systemic vascular resistance in LS group | Secondary inotrope and vasoconstrictor need lower in LS group Tracheal intubation time shorter in LS group |
| De Hert et al, 200723                  | Patients with preoperative LVEF ≤30% and to whom CABG and/or valvular surgery was performed | Randomized open label; assessment of outcomes by blinded observers | 0.1 μg·kg⁻¹·min⁻¹ for 19 h | Immediately after release of aortic cross-clamp | Milrinone 0.5 μg·kg⁻¹·min⁻¹ for 83 h | 15 vs. 15 | Stroke volume increased initially similar, but the effect lasted longer in LS group | Need for additional inotropic or mechanical therapy lower in LS group |
| Eriksson et al, 200924                 | Patients with 3-vessel coronary disease and LVEF <50% to whom CABG was performed | Randomized double blind | 12 μg/kg bolus + 0.2 μg·kg⁻¹·min⁻¹ for 24 h | Immediately after induction of anesthesia | Placebo | 30 vs. 30 | Primary weaning from cardiopulmonary bypass successful in 73% vs. 33% in LS and placebo groups, respectively; P = 0.002 | No difference in need for secondary and vasoconstrictor therapy lower in LS group |
| Levin et al, 200925                    | Postoperative LCOS (within 6 h) in patients with preoperative LVEF <25%, to whom CABG was performed | Randomized open label | 10 μg/kg bolus + 0.1 μg·kg⁻¹·min⁻¹ for 24 h | Within 6 h after surgery | Dobutamine 5–12.5 μg·kg⁻¹·min⁻¹ for 24 h | 127 vs. 126 | Postoperative mortality lower in LS group (7.1% vs. 15.9%; P < 0.05) | Lower need for vasoconstrictors (14.2% vs. 32.5%), vasopressors (17.3% vs. 43.6%), and IABP (3.1% vs. 14.2%; P < 0.05 for all) |
| Levin et al, 201226                    | Patients with preoperative LVEF <25% undergoing CABG | Randomized open label | 10 μg/kg bolus + 0.1 μg·kg⁻¹·min⁻¹ for 24 h | 24 h before surgery | Placebo | 127 vs. 125 | Postoperative LCOS (7.1% vs. 20.8%; P < 0.05) and mortality (3.9% vs. 12.8%; P < 0.05) lower in LS group | Difficult weaning from cardiopulmonary bypass, need for secondary inotropes and vasoconstrictors, and need for IABP less frequent in LS group |
TABLE 1. (Continued) Studies on the Use of Levosimendan in Perioperative Settings Included in the Meta-analysis by Harrison et al.17

| First Author, Year of Publication (ref) | Settings | Trial Design | LS Dose | Start of Treatment | Comparator | Patients in LS Arm vs. Comparator | Primary End Points/Evaluations | Secondary End Points/Evaluations |
|-----------------------------------------|----------|--------------|---------|-------------------|------------|----------------------------------|------------------------------|----------------------------------|
| Lomivorotov et al, 201127              | 40 consecutive patients with LVEF <35%, who underw ent CABG, were included | Randomized open label | 12 μg/kg bolus + 0.1 μg/kg⋅min⁻¹ for 24 h | Immediately after induction of anesthesia | IABP 16–18 h before operation | 20 vs. 20 | Cardiac index significantly higher at 5 min after CPB, at the end of the operation, and at 2 and 4 h after perfusion in LS group | LVEF maintained in LS group but decreased in control group after operation |
| Järvelä et al, 200828                  | Patients undergoing aortic valve surgery with or without CABG | Randomized double blind | 0.2 μg/kg⋅min⁻¹ for 24 h | Immediately after induction of anesthesia | Placebo | 12 vs. 12 | Toponin I lower at 6 h after the operation and ICU stay in LS group | LS prevented postoperative decreases in mixed venous saturation and central venous oxygen saturation |
| Lahtinen et al, 201129                | Patients undergoing CABG or valve operation or both | Randomized double-blind | 24 μg/kg bolus + 0.2 μg/kg⋅min⁻¹ for 24 h | Immediately after induction of anesthesia | Placebo | 99 vs. 101 | Heart failure defined as cardiac index <2.0 L⋅min⁻¹⋅m⁻² or failure to wean from CPB | Rescue inotrope and IABP needed less but vasopressor more in LS group |
| Leppikangas et al, 201130             | Patients undergoing aortic valve surgery and CABG; additionally preoperative LVEF <50% or LV thickness >12 mm | Randomized double blind | 12 μg/kg bolus + 0.2 μg/kg⋅min⁻¹ for 24 h | 24 h before surgery | Placebo | 12 vs. 12 | Cardiac index and stroke volume index higher in LS group for the 4 d postoperative period | Rate-pressure index significantly lower in LS group at 24 and 48 h, indicating lower myocardial oxygen demand |
| Momeni et al, 201131                  | Pediatric study on patients between 0 and 5 years old requiring isotropic support for corrective congenital heart surgery under cardiopulmonary bypass | Randomized double blind | 0.05 μg⋅kg⁻¹⋅min⁻¹ | Onset of CPB | Milrinone | 18 vs. 18 | No significant difference between serum lactate levels of groups | No significant difference between heart rate and systolic blood pressure of groups |
| Tritapepe et al, 200632              | Patients undergoing elective CABG | Randomized double blind | 24 μg/kg as a bolus in 10 min | Just before placing patient on CPB | Placebo | 12 vs. 12 | Lower troponin I release ($P < 0.05$) and a higher cardiac index ($P < 0.05$) postoperatively | Length of ICU stay shorter in LS group: 25 (7) vs. 32 (13) h; $P = 0.002$ |
| Tritapepe et al, 200933              | Patients undergoing elective CABG | Randomized double blind | 24 μg/kg as a bolus in 10 min | Just before placing patient on CPB | Placebo | 52 vs. 50 | Length of hospital: Stay and tracheal intubation time shorter in LS group | Troponin I release lower in LS group |

CPB, cardiopulmonary bypass; DM, diabetes mellitus; LS, levosimendan.
support a marketing authorization in the United States and Canada for levosimendan. The study design and objectives were discussed beforehand and agreed with the US Food and Drug Administration (FDA).

The study population consisted of 882 patients with low preoperative LVEF (EF < 35%) undergoing scheduled or urgent cardiac surgery (CABG and/or mitral valve surgery with or without involvement of other valves). All patients were considered at risk of developing postoperative LCOS. Levosimendan (0.2 μg·kg⁻¹·min⁻¹ for 60 minutes, followed by 0.1 μg·kg⁻¹·min⁻¹ for 23 hours) or placebo was started at the induction of anesthesia to assess whether the drug would decrease the development of LCOS and its detrimental consequences.

The study, conducted at 70 sites in Canada and the United States, demonstrated no statistically robust treatment effect on the composite primary end point of death, perioperative myocardial infarction, and need for renal replacement therapy or a mechanical ventricular assist device. However, there were fewer deaths in the levosimendan group: 20/428 (4.7%) versus 30/421 (7.1%), odds ratio 0.64, 95% CI, 0.37–1.13 (P = 0.12). In addition, the levosimendan-treated patients experienced statistically significantly fewer LCOS events (78 vs. 108; P = 0.007) and needed less inotropic support at or beyond 24 hours after initiation of infusion (235 vs. 264; P = 0.02). Cardiac index also improved more in levosimendan-treated patients (2.9 ± 0.6 vs. 2.7 ± 0.7 L·min⁻¹·m⁻²; P < 0.001). Hypotension and atrial arrhythmias were recorded as adverse events with similar frequency in both study groups.

The LEVO-CTS investigators are conducting post hoc analyses in relevant predetermined subsettings (eg, CABG with or without accompanying valve surgery). So far, they have shown data suggesting that in those patients in whom only CABG was performed, mortality was significantly lower in the levosimendan group: 6/284 (2.1%) versus 22/279 (7.9%), hazard ratio 0.259, 95% CI, 0.105–0.640 (P = 0.0016) (Fig. 2).

INTERPRETATION OF THE DATA

Efficacy

The hypotheses tested in all 3 studies were not affirmed, and the primary end points did not differ significantly between the levosimendan and control arms.

It must be noted that the end points used in LEVO-CTS and LICORN were experimental ones. Similar end points have not been used in earlier studies. The LEVO-CTS primary end points were agreed with the FDA, which required the inclusion of clinical events. This notwithstanding, encouraging evidence of efficacy emerged from LEVO-CTS: the lower incidence of LCOS, lesser need for inotropic support by catecholamines, and improvement in CI indicate that levosimendan exhibited efficacy. In CHEETAH, only suggestive signs of improved hemodynamics were noted, but the dose of levosimendan in that study was smaller than those in LEVO-CTS or LICORN or in previous studies in cardiac surgery. The subgroup data from LEVO-CTS (the supplementary material of the publication is available through http://www.nejm.org/doi/full/10.1056/NEJMoal616218) suggest that levosimendan may be more effective in patients in whom only the CABG procedure is performed (and ineffective in valve replacement patients). Also, in line with earlier data, patients with the lowest EF before surgery may benefit most from the treatment. However, this was not observed in the LICORN study, in which no statistically significant difference was found with respect to the primary end point between patients with LVEF <30% or between 30% and 40%.

Although the duration of treatment with inotropic agents was an outcome variable, the LICORN and CHEETAH protocols do not give details of hemodynamic monitoring and specifically when inotrope treatment should be stopped. Regarding the limited efficacy of levosimendan, the regimen used in the trials can be questioned. Both LEVO-CTS and LICORN used a 0.1 μg·kg⁻¹·min⁻¹ infusion for 24 hours without bolus, in conformity with recent recommendations by experts in cardiovascular anesthesia. Several previous studies have used infusion rates of 0.2 μg·kg⁻¹·min⁻¹ with variable bolus doses. Higher doses may have produced greater hemodynamic effects but at the expense of a more potent vasodilatation and consequent hypotension.

In the LICORN trial, inotidators and inopressors were analyzed together as “catecholamines” irrespective of their predominant hemodynamic effect and no doses for the respective drugs were reported. Consequently, it cannot be ruled out that patients with a severe postoperative LCOS receiving high doses of epinephrine and milrinone, and those needing only small doses of norepinephrine on the second day after surgery were both classified as “catecholamine-dependent.”

One additional observation regarding LEVO-CTS and LICORN is that levosimendan therapy was started very shortly before surgery; accordingly, there was only a short time during which levosimendan could exert any preconditioning effect. In some previous studies, and in clinical practice, levosimendan has been administered for up to 24 hours before the start of surgery.

Finally, in the CHEETAH trial, most patients received a relatively low dose of levosimendan while already being treated with high doses of epinephrine and dobutamine. Pretreatment with beta-mimetic drugs has been shown to reduce the inotropic effect of levosimendan in vitro and thereby may also reduce its benefits in vivo, as shown by Bonios et al in a trial comparing the event-free survival of patients treated with levosimendan, dobutamine, or their combination.

Safety

Safety was not identified as a concern in any of these 3 studies: there was no significant excess of arrhythmias or hypotension and no increase in mortality in levosimendan-treated patients. In fact, mortality was numerically lower in levosimendan-treated patients in LEVO-CTS.

These findings are fully consistent with the data on safety and adverse events reported in most of the previous studies (as collected in a systematic review and meta-analysis by Landoni et al and confirm levosimendan as the safest agent among the family of inotropes and inodilators which include, among others, dobutamine and milrinone). When an inotrope is needed, the safety profile of the chosen agent should be an important selection criterion.
In addition, levosimendan has a unique mechanism of action and pharmacokinetics. The sensitization of myofilaments to calcium supposes that the inotropic effects occur without (or with minimal) increase in myocardial oxygen consumption. The prolonged effect which lasts for several days,\(^{23,43}\) contrasts with the on–off action of dobutamine. These specificities may prove useful in selected patients and are a major reason to keep levosimendan in the armamentarium of physicians in charge of patients with cardiac dysfunction.

**DISCUSSION**

Although the many smaller trials conducted in the past produced as a whole a promising image of levosimendan in perioperative settings, the data from the latest (and larger) 3 studies did not support the hypotheses tested.

Instead of advocating the “small-study effect,” that is, the trend for smaller studies to show larger treatment effects,\(^44\) every study should be evaluated fairly, as large studies can be imprecise, just as small ones can be precise.\(^45\)

Indeed, in small monocentric trials focused on a few end points in very specific clinical settings, the researchers are in a more controlled situation than in a multicenter trial in the field. In addition, in clinical settings, where there are local variations in therapeutic approaches and tailored strategies (such as, for example, in mitral valve surgery\(^46\)), multicenter trials add, by definition, statistical noise to many end points: variations in pharmacologic and nonpharmacologic parameters have the potential to impair the statistical power and obscure meaningful effects. Multicenter studies in fields such as perioperative LCOS, where multiple sources of heterogeneity exist (eg, symptoms, etiologies, comorbidities, comedication, and center-specific treatment practices), encounter such problems.

All the above notwithstanding, we have noticed that studies of all sizes on levosimendan have produced some common and consistent findings in terms of safety. Levosimendan is safe and well tolerated in patients undergoing cardiac surgery with cardiopulmonary bypass who have low LVEF and are at risk of the development of postoperative LCOS. This safety finding, and especially the lack of any deterioration in survival, is particularly noteworthy given that many of the patients in all 3 trials had already been treated with a range of other pressor and/or inotropic drugs. The nonattainment of the study hypotheses in these 3 recent trials does not rule out the fact that levosimendan might be effective in selected patients undergoing cardiac surgery. The LEVO-CTS study, as the largest of these trials, confirms that a prophylactic infusion of levosimendan started immediately before surgery reduces LCOS in a heterogeneous population of cardiac surgery patients with reduced LVEF. The post hoc analyses further suggest that this drug may be especially useful in patients undergoing CABG with reduced LVEF but not in those undergoing a valve surgery. A recent meta-analysis, including also the latest trials, confirms that levosimendan had a significant effect on mortality only when used in case of severe perioperative

| Clinical outcomes | No. of studies | No. of patients | Levosimendan Events Total | Control Events Total | Risk ratio (M-H, random effect) | Risk ratio (M-H, random effect) 95% CI | i(%) | p value |
|------------------|----------------|----------------|--------------------------|---------------------|--------------------------------|----------------------------------------|------|---------|
| **Primary outcomes** |               |                |                          |                     |                                |                                        |      |         |
| 30-days mortality | 4              | 972            | 18                       | 490                 | 0.64                          | 0.36 - 1.16                           | 0    | 0.14    |
| Long-term mortality | 3              | 1134           | 29                       | 572                 | 0.57                          | 0.36 - 0.90                           | 2    | 0.01    |

**FIGURE 2.** Ninety-day mortality among patients in the LEVO-CTS trial in (A) the whole study (n = 849) and (B) the subgroup of isolated CABG patients (n = 563). In the latter, mortality was significantly lower in the levosimendan arm than in the placebo arm, from supplemental materials in Mehta et al.\(^16\) HR, hazards ratio.

**FIGURE 3.** Meta-analysis of clinical trials on levosimendan versus control in cardiac surgery patients with long-term and thirty-day mortality as primary outcome: Effects of levosimendan when used in case of severe perioperative cardiovascular dysfunction (LVEF \(\leq 30\%\)). Sensitivity analysis as in the supplemental material of Lee et al.\(^47\)
cardiovascular dysfunction (LVEF \( \leq 30\% \)) in patients receiving cardiac surgery (Fig. 3).\(^5\) No comparable data are available for any other drugs with inotropic properties; on the contrary, traditional inotropes are considered to have detrimental effects on outcome.\(^6\)

In addition, levosimendan has been shown to reduce elevated right-sided pressures in various clinical situations.\(^48–50\) Preoperative administration of levosimendan decreased pulmonary artery pressure significantly in patients with right ventricular dysfunction and pulmonary hypertension.\(^51\) As pulmonary hypertension is an important prognostic factor in cardiac surgery associated with increased morbidity and mortality,\(^52\) levosimendan’s efficacy could be pronounced in this subgroup and we warmly suggest to explore this setting.

Finally, it must be registered that in many studies, including relatively large regulatory clinical trials, levosimendan was administered in addition to standard of care (ie, other vasoactive drugs) according to prevailing practice at individual study centers. It would be instructive to perform a post hoc analysis of those data to explore whether combinations of levosimendan with dobutamine or norepinephrine are beneficial.

**CONCLUSIONS**

Taking all the available data into consideration, including the experience of the 3 most recent studies, our conclusion is that levosimendan is a safe and effective agent for the treatment of patients undergoing cardiac surgery and in need for inotropic support (Box 3). However, the magnitude of effect of this agent is not as large as previously thought and 3 large multicenter trials could not rule out their null hypothesis. For this reason, levosimendan cannot be at the moment recommended for routine use in all cardiac surgery settings. Further in-depth assessment of the utility of levosimendan will require additional trials in closely defined patient populations with study designs that mitigate, to the fullest extent possible, any influence of methodological variations in patient management.

**BOX 3.**

**Consensus on Efficacy and Safety of Levosimendan in Operative Settings**

Taking all the available data into consideration, including the experience of these 3 recent studies:

- Levosimendan is a safe agent for the treatment of patients undergoing cardiac surgery and in need for inotropic support, despite the 3 large multicenter trials could not rule out their null hypothesis;
- Levosimendan is an effective agent, as it regards hemodynamic support;
- Statistically significant mortality benefit seems to be limited to subgroups, such as the isolated CABG procedures, and the low-EF patients;
- Further in-depth assessment of the utility of levosimendan will require additional trials in closely defined patient populations with study designs that mitigate to the fullest extent as possible any influence of methodological variation.

**ACKNOWLEDGMENTS**

Hughes associates (Oxford, United Kingdom) provided editorial assistance in the preparation of this article.

**REFERENCES**

1. Pease RM, Moreno RP, Bauer P, et al; European Surgical Outcomes Study (EuSOS) Group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7-day cohort study. Lancet. 2012;380:1093–1096.
2. Coulson TG, Bailey M, Reid CM, et al. The association between perioperative acute risk change (ARC) and long-term survival after cardiac surgery. Anaesthesia. 2017;72:1467–1475.
3. Pérez Vela JL, Jiménez Rivero JJ, Alcalá Lorente MA, et al; en representación del Grupo ESBAGA. Low cardiac output syndrome in the postoperative period of cardiac surgery. Profile, differences in clinical course and prognosis. The ESBAGA study. Med Intensiva. 2017. doi: 10.1016/j.medin.2017.05.009. [Epub ahead of print].
4. Algarini KD, Maganti M, Yao TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg. 2011;92:1678–1684.
5. Hannan EL, Wu C, Bennett EV, et al. Risk index for predicting inhospital mortality for cardiac valve surgery. Ann Thorac Surg. 2007;83:921–929.
6. Hills LD, Smith PK, Anderson JL, et al. ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124:e652–e755.
7. Nielsen DV, Hansen MK, Johnsen SP, et al. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology. 2014;120:1098–1108.
8. Papp Z, Edes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications. A consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82–87.
9. Pääkkönen K, Annila A, Sorsa T, et al. Solution structure and main chain dynamics of the regulatory domain (residues 1–91) of human cardiac troponin C. J Biol Chem. 1998;273:15633–15638.
10. Sorsa T, Pollesello P, Permi P, et al. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol. 2003;35:1055–1061.
11. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol. 2002;40:323–338.
12. Toller W, Heringlake M, Guaraccino F, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol. 2015;184:323–336.
13. Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan is associated with improved kidney function after cardiac surgery—a retrospective analysis. J Cardiothorac Surg. 2014;9:167.
20. Al-Shawaf E, Ayed A, Vislocky I, et al. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiovasc Thorac Anesth. 2006;20:353–357.

21. Alvarez J, Taboada M, Rodríguez J, et al. Hemodynamic effects of levosimendan following cardiac surgery. Rev Esp Anestesiol Reanim. 2005;52:389–394.

22. Alvarez J, Bouzada M, Fernández AL, et al. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev Esp Cardiol. 2006;59:338–345.

23. De Hert SG, Lorsomradee S, Cromheecke S, et al. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007;104:766–773.

24. Eriksson HI, Julonen JR, Heikkinen LO, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009;87:448–454.

25. Levin R, Porcel R, Salvagio F, et al. Levosimendan reduces mortality in postoperative low cardiac output syndrome after coronary surgery. Circulation. 2009;120(suppl 18):S987–S988.

26. Levin R, Degrange M, Del Mazo C, et al. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17:125–130.

27. Lonivorotov VV, Cherniavskiy AM, Boboshko VA, et al. Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery. Asian Cardiovasc Thorac Ann. 2011;19:154–159.

28. Järvelä K, Maaranen P, Sisto T, et al. Levosimendan in aortic valve surgery: cardiac performance and recovery. J Cardiovasc Thorac Anesth. 2008;22:693–698.

29. Lahtinen P, Pitkänen O, Pihlön P, et al. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Crit Care Med. 2005;39:2263–2270.

30. Leppikangas H, Järvelä K, Sisto T, et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. Br J Anaesth. 2011;106:298–304.

31. Momeni M, Rubay J, Matta A, et al. Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial. J Cardiovasc Thorac Anesth. 2011;25:419–424.

32. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting—a pilot study. Br J Anaesth. 2006;96:694–700.

33. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102:198–204.

34. Severi L, Lappa A, Landoni G, et al. Levosimendan versus intra-aortic balloon pump in high-risk cardiac surgery patients. J Cardiovasc Thorac Anesth. 2011;25:632–636.

35. Lonivorotov VV, Boboshko VA, Efremov SM, et al. Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients. J Cardiovasc Thorac Anesth. 2012;26:596–603.

36. Baysal A, Yanartas M, Dogukan M, et al. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiovasc Thorac Anesth. 2014;28:586–594.

37. Erb J, Beuthauser T, Feldheiser A, et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. J Int Med Res. 2014;42:750–764.

38. Anastasiadis K, Antonitsis P, Vranis K, et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interact Cardiovasc Thorac Surg. 2016;23:740–747.

39. Haikala H, Kaheinen P, Levijoki J, et al. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997;34:536–546.

40. Bonios MJ, Terrovitis JV, Drakos SG, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol. 2012;159:225–229.

41. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634–646.

42. Greco T, Calabrò MG, Covello RD, et al. A Bayesian network meta-analysis on the effect of inotrope agents on mortality. Br J Anaesth. 2015;114:746–756.

43. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2002;107:81–86.

44. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–1129.

45. Choi SW, Lam DM. Funnels for publication bias—have we lost the plot? Anesthesiology. 2016;71:338–341.

46. Andalib A, Chetrit M, Eberg M, et al. A systematic review and meta-analysis of outcomes following mitral valve surgery in patients with significant functional mitral regurgitation and left ventricular dysfunction. J Heart Valve Dis. 2016;25:696–707.

47. Lee CT, Lin YC, Yeh YC, et al. Effects of levosimendan for perioperative cardiovascular dysfunction in patients receiving cardiac surgery: a meta-analysis with trial sequential analysis. Intensive Care Med. 2017. Available at: https://doi.org/10.1007/s00134-017-4927-5 [ePub September 7].

48. Kleber FX, Bollmann T, Borst MM, et al. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol. 2009;49:109–115.

49. Ebade AA, Khalil MA, Mohamed AK. Levosimendan is superior to dobutamine as an inotrope in the treatment of pulmonary hypertension for children undergoing cardiac surgery. J Anaesth. 2013;27:334–339.

50. Morelli A, Teboul JL, Maggiori SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med. 2006;34:2287–2293.

51. Guerreo-Orrisch JL, Atienza-Villanueva D, Flores-Vela A, et al. Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase. Ther Clin Risk Manag. 2016;12:623–630.

52. Denault A, Deschamps A, Tardif JC, et al. Pulmonary hypertension in cardiac surgery. Curr Cardiovasc Rev. 2010;6:1–14.